Skip to main content
. Author manuscript; available in PMC: 2014 Nov 5.
Published in final edited form as: Cancer Res. 2009 Apr 21;69(9):3910–3917. doi: 10.1158/0008-5472.CAN-08-0034

Figure 1.

Figure 1

A) Structure of APcK110 [4-{7-(3,5-Dimethyloxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl}-4-fluoro]benzene; B) MTT assay demonstrates inhibition of proliferation of OCI/AML3, and HMC1.2 cells by increasing concentrations of APcK110. OCMM2 cells are marginally affected; C) Effect of SCF-neutralizing antibodies (at concentrations ranging from 0.01 to 1 μg/mL) on OCI/AML3 colony-forming capacity. The figure demonstrates significant stimulation by exogenous SCF (P = 0.043 by Mann-Whitney test) and inhibition of OCI/AML3 colony proliferation (P = 0.029 by Mann-Whitney test at a SCF neutralizing antibody concentrations of 0.1 and 1.0) as well as complete reversal of the inhibition by exogenous SCF; D) Effect of SCF-neutralizing antibodies on OCIM2 cells. SCF and SCF neutralizing antibodies do not affect OCIM2 cell proliferation.